elafin and Purpura

Severe cutaneous adverse reactions (SCARs) are frequent in inpatient oncology. Early intervention might reduce morbidity, mortality, and hospitalization costs; however, current clinical and histologic features are unreliable SCAR predictors. There is a need to identify rational markers of SCARs that could lead to effective therapeutic interventions.. To characterize the clinical and serologic features of hospitalized patients with cancer who developed SCARs.. Retrospective review of 49 hospitalized cancer patients with a morbilliform rash, recorded testing for serum cytokines (interleukin [IL] 6, IL-10, and tumor necrosis factor [TNF] α) or elafin, and a prior dermatology consultation. Patients were categorized as having a simple morbilliform rash without systemic involvement or complex morbilliform rash with systemic involvement.. Fifteen out of 49 patients (30.6%) were deceased at 6 months from time of dermatologic consultation. Elafin, IL-6, and TNF-α were significantly higher in patients who died compared with patients who were still alive at 6 months. IL-6 and IL-10 were significantly higher in patients with a drug-related complex rash.. Retrospective design, limited sample size, and high-risk patient population.. In cancer patients with SCARs, elafin, IL-6, and TNF-α levels might predict a poor outcome. Agents directed against these targets might represent rational treatments for the prevention of fatal SCARs.

Topics: Adult; Antineoplastic Agents; Biomarkers; Body Surface Area; Cytokines; Drug Hypersensitivity Syndrome; Edema; Elafin; Eosinophilia; Face; Female; Fever; Graft vs Host Disease; Hospital Mortality; Hospitalization; Humans; Interleukin-10; Interleukin-6; Lymphocytes; Male; Neoplasms; Purpura; Retrospective Studies; Stevens-Johnson Syndrome; Tumor Necrosis Factor-alpha